 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| RXMD Launches New Program Creating New Revenue Stream and Expands Reach |
|
 Hot Stock to Watch |
Company: Progressive Care Inc. (OTCQB: RXMD)
|
Last:
Price: 0.065
Change (%): + 0.00 (0.00)
Volume: 285,823 |
 |
Progressive Care Launches New Discharge(RX) Program to Improve Engagement Between Patients and Hospitals
MIAMI, July 10, 2018 (GLOBE NEWSWIRE) - Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced the launch of its new proprietary patient engagement program, DischargeRX, designed to ensure that hospital patients are receiving the best transitional care while preserving vital hospital resources.
According to a 2017 study published in the Journal of the American Pharmacists Association, up to 26% of hospital readmissions are medication-related, creating a much-needed opportunity for a program to be created that is proactive towards patient engagement. Through Progressive Care’s wholly owned subsidiaries, DischargeRX will provide hospitals with much needed support in preventing unnecessary and costly hospital readmissions. At no cost to the hospital or patient, the program will provide access to a PharmCo representative who will offer medication-related services throughout the patient’s transitional process.
Through direct interaction between the patient and PharmCo, the company is able to understand the patient, their healthcare needs, follow-up plans and current drug regimen. After the consultation, recommendations may be made to optimize their prescription therapy through med synchronization and effective packaging options including the use of PharmCo’s SmartPack adherence solution. The patient will be given a full overview of their prescriptions, uses and best methods for staying on track with doses.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
